These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 24877866)

  • 21. [Nucleos (t) ide analogue/interferon sequential therapy for chronic hepatitis B].
    Matsumoto A
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():521-5. PubMed ID: 26845989
    [No Abstract]   [Full Text] [Related]  

  • 22. Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice.
    Lampertico P
    J Hepatol; 2009 Apr; 50(4):644-7. PubMed ID: 19231017
    [No Abstract]   [Full Text] [Related]  

  • 23. Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients.
    Wang HM; Hung CH; Lee CM; Lu SN; Wang JH; Yen YH; Kee KM; Chang KC; Tseng PL; Hu TH; Chen CH
    J Gastroenterol Hepatol; 2016 Jul; 31(7):1307-14. PubMed ID: 26758501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.
    Cheung KS; Seto WK; Wong DK; Lai CL; Yuen MF
    J Viral Hepat; 2017 Aug; 24(8):654-661. PubMed ID: 28185363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of chronic hepatitis B in children: an unresolved issue.
    Della Corte C; Nobili V; Comparcola D; Cainelli F; Vento S
    J Gastroenterol Hepatol; 2014 May; 29(5):912-9. PubMed ID: 24863185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B.
    Wong GL; Wong VW; Chan HL
    J Viral Hepat; 2014 Dec; 21(12):825-34. PubMed ID: 25402543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver cirrhosis stages and the incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral therapy.
    Shim JJ; Oh CH; Kim JW; Lee CK; Kim BH
    Scand J Gastroenterol; 2017 Sep; 52(9):1029-1036. PubMed ID: 28562104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Improved survival and less hepatocellar carcinoma following the successful treatment of chornic hepatitis B].
    Jansen PL
    Ned Tijdschr Geneeskd; 2005 Jul; 149(27):1495-7. PubMed ID: 16032993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of end-stage liver disease in chronic hepatitis B.
    Tan HH; Martin P
    Clin Liver Dis; 2010 Aug; 14(3):477-93. PubMed ID: 20638026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Problems of resistance during treatment of chronic hepapitis B with nucleoside and nucleotide analogues: diagnostics, prophylactics and treatment].
    Abdurakhmanov DT
    Eksp Klin Gastroenterol; 2007; (4):74-81. PubMed ID: 18411444
    [No Abstract]   [Full Text] [Related]  

  • 31. Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs.
    Brown A; Goodman Z
    Expert Rev Gastroenterol Hepatol; 2012 Apr; 6(2):187-98. PubMed ID: 22375524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular virology in chronic hepatitis B: genotypes.
    Wong GL; Chan HL
    Hosp Med; 2005 Jan; 66(1):13-6. PubMed ID: 15686160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B.
    Kim WR; Loomba R; Berg T; Aguilar Schall RE; Yee LJ; Dinh PV; Flaherty JF; Martins EB; Therneau TM; Jacobson I; Fung S; Gurel S; Buti M; Marcellin P
    Cancer; 2015 Oct; 121(20):3631-8. PubMed ID: 26177866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B.
    Hsu YC; Wu CY; Lane HY; Chang CY; Tai CM; Tseng CH; Lo GH; Perng DS; Lin JT; Mo LR
    J Antimicrob Chemother; 2014 Jul; 69(7):1920-7. PubMed ID: 24576950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic hepatitis B: who to treat and which choice of treatment?
    Di Marco V; Craxì A
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):281-91. PubMed ID: 19344242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does chemotherapy prevent HBV-related hepatocellular carcinoma? Pros.
    Liaw YF
    Dig Liver Dis; 2010 Jul; 42 Suppl 3():S293-7. PubMed ID: 20547317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides.
    Patwardhan VR; Sengupta N; Bonder A; Lau D; Afdhal NH
    Aliment Pharmacol Ther; 2014 Oct; 40(7):804-10. PubMed ID: 25109610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B.
    Nagata N; Kagawa T; Hirose S; Arase Y; Tsuruya K; Anzai K; Shiraishi K; Mine T
    BMC Gastroenterol; 2016 Mar; 16():38. PubMed ID: 26987437
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.
    Sung JJ; Tsoi KK; Wong VW; Li KC; Chan HL
    Aliment Pharmacol Ther; 2008 Nov; 28(9):1067-77. PubMed ID: 18657133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacotherapeutic options for hepatitis B.
    Chen YC; Liaw YF
    Expert Opin Pharmacother; 2016; 17(3):355-67. PubMed ID: 26559942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.